Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Financial Group Inc (AFG) vs AstraZeneca plc (AZN) Price & Performance

American Financial Group Inc
AstraZeneca plc

Price performance

Price movement over the last 24 hours

Key statistics

American Financial Group Inc vs AstraZeneca plc — how do they compare? American Financial Group Inc trades at $141.19 (market cap $11.86B), while AstraZeneca plc trades at $189.84 (market cap $294.08B). The key difference: AstraZeneca plc is far larger — about 24.8× American Financial Group Inc's market cap, and American Financial Group Inc pays the higher dividend (2.46%). Which is the better fit depends on your goals.

AFGAZN
Market Cap
$11.86B$294.08B
Sector
FinancialsHealth
52-Week High
$148.71$209.48
52-Week Low
$122.42$137.44
Enterprise Value
$12.33B$320.32B
Dividend Yield
2.46%1.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Financial Group Inc

AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.

AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.

AstraZeneca plc

AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.

AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Financial Group Inc

American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.

Read more on AFG

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN